The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials

Autor: Eva MM Strijbis, Pavle Repovic, Jop Mostert, James D Bowen, Bernard MJ Uitdehaag, Gary Cutter, Marcus W Koch

Publikováno v: Multiple Sclerosis Journal, 28(10), 1606-1619. SAGE Publications Ltd
Strijbis, E M M, Repovic, P, Mostert, J, Bowen, J D, Uitdehaag, B M J, Cutter, G & Koch, M W 2022, ' The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials ', Multiple Sclerosis Journal, vol. 28, no. 10, pp. 1606-1619 . https://doi.org/10.1177/13524585221105465

Background: Patient-reported outcome measures (PROMs) are often used in clinical research, but little is known about their performance as longitudinal outcomes. Methods: We used data from ASCEND, a large SPMS trial ( n = 889), to investigate changes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f884d134aaccd214afc529979b8d6d5c
http://www.scopus.com/inward/record.url?scp=85134989329&partnerID=8YFLogxK

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

Autor: Alyssa A Toorop, Theo Rispens, Eva MM Strijbis, Bob W van Oosten, Brigit A de Jong, Bernard MJ Uitdehaag, Joep Killestein, Zoé LE van Kempen

Publikováno v: Multiple Sclerosis Journal. SAGE Publications Ltd
Multiple Sclerosis (Houndmills, Basingstoke, England)
Toorop, A A, Rispens, T, Strijbis, E M M, van Oosten, B W, de Jong, B A, Uitdehaag, B M J, Killestein, J & van Kempen, Z L E 2021, ' Natalizumab concentrations during pregnancy in three patients with multiple sclerosis ', Multiple Sclerosis Journal . https://doi.org/10.1177/13524585211052168

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9910ddf91621ae7cc01668a003aba1d5
https://research.vumc.nl/en/publications/fa1b4359-5857-4374-a72c-f2045a280df4

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.

Autor: van Lierop, Zoë YGJ, Wessels, Mark HJ, Lekranty, Womei ML, Moraal, Bastiaan, Hof, Sam N, Hogenboom, Laura, de Jong, Brigit A, Meijs, Nandi, Mensing, Liselore A, van Oosten, Bob W, Sol, Nik, van Kempen, Zoé LE, Vermunt, Lisa, Willems, Myrthe J, Strijbis, Eva MM, Uitdehaag, Bernard MJ, Killestein, Joep, Teunissen, Charlotte E

Publikováno v: Multiple Sclerosis Journal; Nov2024, Vol. 30 Issue 13, p1620-1629, 10p

Study Data from Amsterdam University Medical Center Update Knowledge of Multiple Sclerosis (Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple...).

Publikováno v: Clinical Trials Week; 11/18/2024, p2072-2072, 1p

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT- MS).

Autor: Toorop, Alyssa A., van Lierop, Zoë Y. G. J., Gelissen, Liza M. Y., Hoitsma, Elske, Zeinstra, Esther M. P. E., van Rooij, Luuk C., van Munster, Caspar E. P., Vennegoor, Anke, Mostert, Jop P., Wokke, Beatrijs H. A., Kalkers, Nynke F., Hoogervorst, Erwin L. J., van Eijk, Jeroen J. J., Roosendaal, Christiaan M., Kragt, Jolijn J., Eurelings, Marijke, van Genugten, Jessie, Nielsen, Jessica, Sinnige, L. G. F., Kloosterziel, Mark E.

Publikováno v: Journal of Neurology, Neurosurgery & Psychiatry; May2024, Vol. 95 Issue 5, p392-400, 9p